Introduction
============

Telomerase, a RNA-dependent DNA polymerase, adds repeat segments to the end of linear chromosomes stabilizing the length of telomere and enabling the immortalization of malignant cells.[@b1-ott-9-6965] Telomerase reverse transcriptase (TERT) is a rate-limiting catalytic subunit of telomerase complex taking part in telomerase reactivation and telomere elongation.[@b2-ott-9-6965],[@b3-ott-9-6965] Overexpression of TERT and activation of telomerase are found in various malignancies, which are linked to cancer hallmarks including proliferation, anti-apoptosis, angiogenesis, invasion, and metastasis.[@b4-ott-9-6965],[@b5-ott-9-6965] Two mutations in −124 bp (chr5: 1,295,228; termed C228T) and −146 bp (chr5: 1,295,250; termed C250T) upstream from the translation start site of *TERT* gene have been identified in melanomas[@b6-ott-9-6965],[@b7-ott-9-6965] and have further been found in glioma,[@b8-ott-9-6965],[@b9-ott-9-6965] liposarcoma,[@b9-ott-9-6965] urothelial carcinoma,[@b8-ott-9-6965],[@b10-ott-9-6965] hepatocellular carcinoma,[@b8-ott-9-6965],[@b11-ott-9-6965] and thyroid cancers.[@b12-ott-9-6965]--[@b17-ott-9-6965] Functional research studies showed that *TERT* promoter mutations enhanced the transcriptional activity of the *TERT* promoter, which highly upregulated the mRNA level and increased telomerase activity.[@b8-ott-9-6965] This may be because both mutations generate novel binding sites (GGAA/T) for E-twenty-six (ETS) transcription factors and enhance the transcriptional level, which provides an alternative mechanism of TERT activation.[@b6-ott-9-6965]--[@b8-ott-9-6965]

Thyroid cancer is the most common endocrine malignancy, with an increasing incidence in the last few decades.[@b18-ott-9-6965],[@b19-ott-9-6965] Among the follicular-cell-derived thyroid cancer (FCDTC), papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) are well-differentiated and classified as differentiated thyroid cancer (DTC),[@b20-ott-9-6965] while anaplastic thyroid cancer (ATC) is undifferentiated with limited survival of \<6 months.[@b21-ott-9-6965] Another rare histological type is medullary thyroid cancer (MTC) originating from parafollicular or C cells. Development and progression of thyroid cancer are accompanied by accumulation of genetic and epigenetic alterations which vary from different histological types of thyroid cancer. The aberrant activation of *RET* signaling is the primary mechanism of MTC, while MAPK pathway (mainly triggered by *BRAF*^V600E^ mutations) and PI3K pathway (which can be caused by mutations in *RAS*, *PTEN*, and *PIK3CA*), respectively, lead to PTC and FTC.[@b20-ott-9-6965] *TERT* promoter mutations also participate in the carcinogenesis of thyroid cancer, and the frequency ranges from 9% to 37% in different studies.[@b12-ott-9-6965]--[@b14-ott-9-6965],[@b16-ott-9-6965],[@b17-ott-9-6965],[@b22-ott-9-6965] Although the clinicopathological and prognostic significance of *TERT* promoter mutations have been investigated in various research studies,[@b14-ott-9-6965]--[@b17-ott-9-6965],[@b22-ott-9-6965],[@b23-ott-9-6965] no consistent conclusion has been achieved.[@b15-ott-9-6965],[@b24-ott-9-6965]--[@b26-ott-9-6965] Besides, some researchers have reported that the coexistence of *BRAF* and *TERT* promoter mutations contributes to more aggressive tumor and worse outcome;[@b15-ott-9-6965],[@b23-ott-9-6965],[@b27-ott-9-6965] however, other researchers have reported contrary results.[@b24-ott-9-6965],[@b28-ott-9-6965]

Therefore, this meta-analysis was conducted to clarify the distribution of *TERT* promoter mutations in different histological types of thyroid cancer and then analyze their association with high-risk clinicopathological features, adverse outcomes, and *BRAF*^V600E^ mutation. Furthermore, the practical values of *TERT* promoter mutations in preoperative diagnosis, risk stratification, prognostic prediction, and therapeutic option were evaluated.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

Systematic searches were performed in PubMed, Web of Science, Scopus, Ovid, and the Cochran Library databases for relevant studies before April 2016. The search terms were: ((thyroid cancer) or (thyroid neoplasm) or (thyroid tumor)) and ((TERT) or (telomerase reverse transcriptase)). Relevant articles and reviews were also inspected for additional studies. Studies were included according to the following criteria: 1) detecting *TERT* promoter mutations in thyroid cancer; 2) data availability of mutation rate, clinicopathological features, prognosis, or *BRAF*^V600E^ mutation; and 3) evaluation of the summary odds ratio (OR) or standardized mean difference (SMD) with 95% confidence interval (CI). Studies were excluded based on these criteria: 1) review, case report, editorial, or comments; and 2) research studies with repeated or unusable data.

Data extraction and quality assessment
--------------------------------------

Details including first author, year of publication, country, number of centers, study design, number of participants, histological type of thyroid cancer, mean age, gender, sample source, sequencing method, cases and duration of follow-up, *BRAF*^V600E^ mutation, clinicopathological features (mean diameter of tumor, extrathyroidal extension, vascular invasion, distant metastasis, lymph node metastasis, and tumor stage), and adverse outcome (persistence/recurrence and disease specific mortality) were obtained from the studies. Tumor stage was standardized by the tumor-node-metastasis (TNM) system of the American Joint Committee on Cancers.[@b25-ott-9-6965] Persistence/recurrence was defined as the presence of abnormality confirmed by pathology. The quality of studies was assessed by two investigators according to the Newcastle--Ottawa scale (NOS) comprising three dimensions: four scores for subject selection, two scores for subject comparability, and three scores for prognostic assessment.[@b26-ott-9-6965] Studies with \>7 scores were regarded as high quality, 4--6 scores were mid-range, and ≤3 were low quality.

Statistical analysis
--------------------

Mutation frequencies were synthesized by R statistical software (version 3.2.1; R Foundation for Statistical Computing, Vienna, Austria). OR and SMD, respectively, quantify the association between *TERT* promoter mutations and dichotomous variables (gender, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, stage, recurrence/persistence, mortality, and *BRAF*^V600E^ mutation) and continuous variables (age and tumor size). Pooled OR and SMD with 95% CI were achieved by STATA (version 12.0; Stata Corporation, College Station, TX, USA). The potential heterogeneity was evaluated by Cochrane Q test and inconsistency index (*I*^2^). *I*^2^\>50% suggested significant heterogeneity and so random effects model (DerSimonian--Laird method) was chosen; otherwise, fixed effects model (Mantel--Haenszel method) would be considered.[@b29-ott-9-6965] Continuous data were pooled by Cohen method for SMD when the number of studies \>10 (both fixed effects model and random effects model). For all analyses, *P*\<0.05 was regarded as statistically significant.

Results
=======

Search results and quality assessment
-------------------------------------

A flowchart of the literature research is shown in [Figure 1](#f1-ott-9-6965){ref-type="fig"}. A total of 1,106 articles were initially included. After removal of the duplicates, 894 studies remained. Then, 854 studies were excluded after reviewing the titles and abstracts. Full-text of the remaining 40 studies were further evaluated, and 22 studies with 4,907 patients were ultimately included in this meta-analysis.[@b12-ott-9-6965]--[@b17-ott-9-6965],[@b22-ott-9-6965],[@b23-ott-9-6965],[@b27-ott-9-6965],[@b30-ott-9-6965]--[@b42-ott-9-6965] All the 22 studies reported the frequency of *TERT* promoter mutations,[@b12-ott-9-6965]--[@b17-ott-9-6965],[@b22-ott-9-6965],[@b23-ott-9-6965],[@b27-ott-9-6965],[@b30-ott-9-6965]--[@b42-ott-9-6965] 18 studies were available for analyzing the clinicopathological features and prognostic significance,[@b14-ott-9-6965]--[@b17-ott-9-6965],[@b22-ott-9-6965],[@b23-ott-9-6965],[@b27-ott-9-6965],[@b31-ott-9-6965]--[@b33-ott-9-6965],[@b35-ott-9-6965]--[@b42-ott-9-6965] 15 studies investigated the relationship of *TERT* promoter and *BRAF*^V600E^ mutations,[@b13-ott-9-6965],[@b15-ott-9-6965],[@b16-ott-9-6965],[@b22-ott-9-6965],[@b23-ott-9-6965],[@b27-ott-9-6965],[@b33-ott-9-6965]--[@b37-ott-9-6965],[@b39-ott-9-6965]--[@b42-ott-9-6965] and six of them evaluated the synergetic effect of both mutations.[@b15-ott-9-6965],[@b24-ott-9-6965],[@b25-ott-9-6965],[@b35-ott-9-6965],[@b37-ott-9-6965],[@b41-ott-9-6965] According to the NOS system, 11 studies were classified as high-quality and the other 11 were mid-range. Main characteristics and methodological quality of all the 22 studies are listed in [Table 1](#t1-ott-9-6965){ref-type="table"} according to the publication year. The structures of *TERT* core promoter and BRAF protein kinase are shown in [Figure 2](#f2-ott-9-6965){ref-type="fig"}.

Distribution of *TERT* promoter mutations in thyroid cancer
-----------------------------------------------------------

[Table 2](#t2-ott-9-6965){ref-type="table"} summarized the distribution of *TERT* promoter mutations in different histological types of thyroid cancer. Random effects model was used in the analysis with obvious heterogeneity (*I*^2^\>50%); otherwise, the fixed effects model was chosen. The *TERT* promoter mutations only existed in FCDTC, but were absent in MTC and benign lesions (data not shown). Two types of *TERT* promoter mutation (C228T and C250T) were mutually exclusive. Besides, C228T (0.1126; 95% CI 0.0820--0.1433) was more common than C250T (0.0271; 95% CI 0.0174--0.0368). Their frequencies in poorly differentiated thyroid cancer (PDTC) (0.3337; 95% CI 0.2068--0.4606) and ATC (0.3869; 95% CI 0.2866--0.4872) were three times higher than that in DTC (0.1091; 95% CI 0.0819--0.1363). And the rate in FTC (0.1703; 95% CI 0.1277--0.2128) was nearly twice in PTC (0.0941; 95% CI 0.0716--0.1165). Among the subcategories of PTC, tall-cell PTC (TCPTC, 0.3023; 95% CI 0.1650--0.4396) harbored especially higher rate than conventional (0.0342; 95% CI 0.0362--0.1490) and follicular variant (0.0809; 95% CI 0.0207--0.1824) PTCs.

Clinicopathological and prognostic significance of *TERT* promoter mutations
----------------------------------------------------------------------------

Age, gender, tumor size, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, tumor stage, persistence/recurrence, and mortality were obtained from the studies 11, 16, 7, 8, 4, 14, 8, 12, 8, and 5, respectively. Fixed effects model was used in the analysis of gender, vascular invasion, persistence/recurrence, and mortality, while random effects model was chosen for the other analyses.

As shown in [Figure 3](#f3-ott-9-6965){ref-type="fig"}, *TERT* promoter mutations tended to present in older patients (SMD 0.79; 95% CI 0.61--0.96) and males (OR 1.64; 95% CI 1.31--2.05). Besides, they were relevant to larger tumor size (SMD 0.67; 95% CI 0.31--1.04), extrathyroidal extension (OR 2.86; 95% CI 1.68--4.86), vascular invasion (OR 1.81; 95% CI 1.22--2.68), lymph node metastasis (OR 1.80; 95% CI 1.11--2.91), distant metastasis (OR 8.19; 95% CI 4.11--16.32), and advanced tumor stage (OR 5.39; 95% CI 2.90--10.00). They also indicated adverse outcomes including tumor persistence/recurrence (OR 3.75; 95% CI 2.58--5.45) and disease-related mortality (OR 8.39; 95% CI 4.13--17.03).

Relationship of *TERT* promoter and *BRAF*^V600E^ mutations
-----------------------------------------------------------

As shown in [Figure 4](#f4-ott-9-6965){ref-type="fig"}, *TERT* promoter mutations were likely to occur in *BRAF*^V600E^-positive thyroid cancer (OR 1.88; 95% CI 1.41--2.51), which was especially obvious in C228T (OR 2.53; 95% CI 1.77--3.62) rather than C250T mutation (OR 0.64; 95% CI 0.13--3.06). Random effects model was used to evaluate the association between *BRAF*^V600E^ and C250T mutations.

Patients harboring both *TERT* promoter and *BRAF*^V600E^ mutations tended to be male (OR 3.71; 95% CI 1.66--8.29) and have larger tumor size (SMD 0.80; 95% CI 0.24--1.35), extrathyroidal extension (OR 5.85; 95% CI 2.14--16.01), and advanced tumor stage (OR 7.90; 95% CI 3.22--19.37) in comparison with patients with *TERT* promoter mutations only ([Table 3](#t3-ott-9-6965){ref-type="table"}). When compared with patients having *BRAF*^V600E^ mutation only, patients harboring both *TERT* and *BRAF*^V600E^ mutations seemed to be older patients (SMD 0.77; 95% CI 0.40--1.15) and males (OR 2.38; 95% CI 1.59--3.56) and tended to suffer from extrathyroidal extension (OR 5.76; 95% CI 3.45--9.63), lymph node metastasis (OR 1.58; 95% CI 1.01--2.47), distant metastasis (OR 13.07; 95% CI 2.57--66.59), advanced tumor stage (OR 4.22; 95% CI 2.71--6.58), recurrence/persistence (OR 8.50; 95% CI 4.20--17.19), and mortality (OR 8.14; 95% CI 2.38--27.89) ([Table 3](#t3-ott-9-6965){ref-type="table"}).

Discussion
==========

The majority of thyroid cancer has excellent prognosis after thyroidectomy with/without radioiodine ablation.[@b43-ott-9-6965] However, a small group of patients suffer from unfavorable outcome.[@b44-ott-9-6965],[@b45-ott-9-6965] During the pathogenesis and progression of thyroid cancer, a number of genetic and epigenetic alterations are accumulated. These alterations provide potential biomarkers to discriminate aggressive cases from those with indolent behavior. In recent years, the clinicopathological and prognostic significance of *TERT* promoter mutations have been widely evaluated in thyroid cancer, and the discrepancies among studies are probably caused by small sample size of individual studies.[@b14-ott-9-6965]--[@b17-ott-9-6965],[@b22-ott-9-6965],[@b23-ott-9-6965] This meta-analysis demonstrated that *TERT* promoter mutations were likely to aggregate in aggressive histological types and associated with high-risk clinicopathological features and adverse outcome of thyroid cancer. The present study also confirmed the coexistence of *TERT* promoter (C228T) and *BRAF*^V600E^ mutations, which contributed to more aggressive tumor behavior. De-Tao et al conducted a similar meta-analysis recently, but it only included 8 studies comprising 2,035 patients and excluded studies analyzing fine-needle aspiration biopsy (FNAB) which was an important and reliable diagnostic approach for thyroid cancer.[@b46-ott-9-6965] Another study conducted by Liu and Xing also achieved brilliant results.[@b47-ott-9-6965] However, almost all of the studies were based on Americans and Europeans, except one from Saudi Arabia. This meta-analysis included five additional studies from Asia, which may be complementary because of the different genetic background among ethnicities.

*TERT* promoter mutations were exclusively present in FCDTC. Previous researchers propose that *TERT* promoter mutations usually exist in malignancies originating from terminally differentiated cells with low self-renewing capacity,[@b9-ott-9-6965] while the rapidly renewing tissues have alternative mechanisms for telomere elongation and are less dependent on TERT activation.[@b48-ott-9-6965] In addition, this study showed that *TERT* promoter mutations were absent in normal tissues or benign lesions; thus they can serve as biomarkers having high specificity for malignancy. However, the diagnostic efficiency may be severely limited by the low prevalence of *TERT* promoter mutations in DTC.[@b30-ott-9-6965] Liu and Xing and Crescenzi et al, respectively, evaluated the feasibility of *TERT* promoter mutations in preoperative FNAB and core needle biopsies and found it can improve the diagnostic efficiency for indeterminate nodules.[@b30-ott-9-6965],[@b32-ott-9-6965],[@b34-ott-9-6965] A previous study found that *BRAF*^V600E^ mutation had no significant value for indeterminate nodules classified as follicular neoplasm/suspicious for follicular neoplasm (FN/SFN).[@b49-ott-9-6965] In this meta-analysis, the frequencies of *TERT* promoter mutations in FTC and FVPTC, the main components of malignant FN/SFN nodules, were found to be 17.03% and 8.09%, respectively. Therefore, *TERT* promoter mutations may be helpful to diagnose thyroid cancer in FN/SFN nodules.

*TERT* promoter mutations tended to aggregate in aggressive histological types (ATC, PDTC, and TCPTC) and were significantly associated with high-risk features and adverse outcome. Furthermore, the coexistence of *BRAF*^V600E^ and *TERT* promoter mutations indicated more aggressive tumor and worse prognosis, and the influence of *TERT* promoter mutations seemed to be more significant than *BRAF*^V600E^ mutation. The mechanism underlying the synergetic effect of *BRAF* and *TERT* promoter mutations remains uncertain.[@b15-ott-9-6965],[@b24-ott-9-6965],[@b25-ott-9-6965],[@b29-ott-9-6965],[@b30-ott-9-6965],[@b39-ott-9-6965],[@b50-ott-9-6965] Vinagre et al and Bullock et al demonstrated that *BRAF* and *TERT* promoter mutations can increase the expression of each other,[@b17-ott-9-6965],[@b37-ott-9-6965] which may be achieved by activation of *MAPK* pathway and regulation of ETS transcriptional factors.[@b50-ott-9-6965] Li et al found that C250T mutation alone was insufficient to drive the transcription of *TERT* gene and required noncanonical NF-κB signaling for stimulus responsiveness at the same time.[@b51-ott-9-6965] Therefore, the functions of C228T and C250T mutations were distinct, which partially explained the result that no significant association was found between *BRAF* and C250T mutations. Therefore, *TERT* promoter mutations can distinguish not only malignancy but also aggressive cases that need more positive therapeutic approach and vigilant monitoring. Some researchers also reported that patients with *TERT* promoter mutations tended to suffer from radiotherapeutic resistance;[@b39-ott-9-6965],[@b52-ott-9-6965] so *TERT* promoter mutations might also be potential predictors for therapeutic efficiency.

Limitations
===========

There were some limitations in this meta-analysis. First, most of the studies were retrospectively designed which may cause potential selection bias to better-documented patients and larger tumors since they were more available for collection and analysis. Second, heterogeneity was present in some analyses probably due to confounding factors such as sample size, ethnicity, patients' age, tumor size, sample source, and so on. Besides, most of the aggressive variables are interrelated; so the results should be interpreted cautiously.

Conclusion
==========

This meta-analysis confirmed that *TERT* promoter mutations were more frequent in aggressive histological types of thyroid cancer. And they were likely to present in older patients and males and strongly associated with larger tumor size, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, advanced tumor stage, disease recurrence/persistence, and mortality. *TERT* promoter mutations seemed to coexist with *BRAF* mutation, which contributed to more aggressive tumor and worse prognosis. Therefore, *TERT* promoter mutations have the potential to serve as biomarkers assisting preoperative diagnosis, risk stratification, prognostic prediction, and individualizing therapeutic option or follow-up design of thyroid cancer.
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![Flowchart of study selection process.\
**Abbreviation:** TERT, telomerase reverse transcriptase.](ott-9-6965Fig1){#f1-ott-9-6965}

![Schematic representation of TERT core promoter and BRAF protein kinase.\
**Notes:** (**A**) The C228T and C250T mutations are located in −124 bp and −146 bp upstream from the TSS, which induce novel ETS binding sites. (**B**) There were three conserved regions (CR1, 2, 3) in the BRAF protein kinase. CR1 and CR2 are regulatory domains and CR3 is the catalytic domain. RBD and CRD are located in CR1. The N-region, glycine-rich loop, and activation segment are located in CR3. BRAF^V600E^ is located in the activation segment.\
**Abbreviations:** TERT, telomerase reverse transcriptase; TSS, translation start site; ETS, E-twenty-six; RBD, Ras-binding domain; CRD, cystein-rich domain.](ott-9-6965Fig2){#f2-ott-9-6965}

###### 

Forest plot showing the association of *TERT* promoter mutations with clinicopathological features and adverse outcomes.

**Notes:** Weights are from random effects analysis; Weights are from fixed effects analysis.

**Abbreviations:** TERT, telomerase reverse transcriptase; SMD, standardized mean difference; OR, odds ratio; CI, confidence interval; *I*^2^, inconsistency index.
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![Forest plot showing the relationship of *TERT* promoter mutations and *BRAF* mutation.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** TERT, telomerase reverse transcriptase; OR, odds ratio; CI, confidence interval; *I*^2^, inconsistency index.](ott-9-6965Fig4){#f4-ott-9-6965}

###### 

Characteristics and methodological quality of 22 studies included in the meta-analysis

  Study                              Year   Country        Study design   Number of centers   Number of cases   Histotype   Mean age (years)   Sex (F/M)   *TERT* mutation     Follow-up           Quality (NOS)                 
  ---------------------------------- ------ -------------- -------------- ------------------- ----------------- ----------- ------------------ ----------- ------------------- ------------------- --------------- ----- ------- ---
  Landa et al[@b12-ott-9-6965]       2013   USA            Retro          Multiple            183               TC          NA                 NA          Surgical specimen   Direct sequencing   C228T + C250T   NA    NA      4
  Liu et al[@b13-ott-9-6965]         2013   USA            NA             NA                  414               TC          NA                 NA          Surgical specimen   Direct sequencing   C228T + C250T   NA    NA      6
  Vinagre et al[@b17-ott-9-6965]     2013   Portugal       Retro          Multiple            263               TC          48                 189/61      FFPE                Direct sequencing   C228T + C250T   NA    NA      6
  Liu and Xing[@b30-ott-9-6965]      2014   USA            Pro            Single              129               DTC         NA                 NA          FNAB                Direct sequencing   C228T + C250T   NA    NA      5
  Liu et al[@b14-ott-9-6965]         2014   Sweden         Retro          Single              144               TC          NA                 NA          Surgical specimen   Direct sequencing   C228T + C250T   51    NA      9
  Liu et al[@b15-ott-9-6965]         2014   USA            Retro          Multiple            430               DTC         NA                 NA          FFPE                Direct sequencing   C228T + C250T   NA    NA      5
  Melo et al[@b16-ott-9-6965]        2014   Portugal       Retro          Multiple            469               FCDTC       48.2               342/117     FFPE                Direct sequencing   C228T + C250T   469   93.6    8
  Wang et al[@b31-ott-9-6965]        2014   Sweden         Retro          Single              52                FTC         53.19              33/19       Surgical specimen   Direct sequencing   C228T + C250T   52    111     8
  Xing et al[@b23-ott-9-6965]        2014   USA            Retro          Single              507               PTC         45.9               365/142     FFPE                Direct sequencing   C228T           507   24      8
  Crescenzi et al[@b32-ott-9-6965]   2015   Italy          Retro          Multiple            30                PTC         NA                 NA          CNB                 Direct sequencing   C228T + C250T   NA    NA      5
  De Biase et al[@b33-ott-9-6965]    2015   Italy          Retro          Multiple            404               PTC         NA                 294/82      FFPE                NGS                 C228T + C250T   306   58      8
  Dettmer et al[@b34-ott-9-6965]     2015   Switzerland    Retro          Multiple            125               PTC         NA                 91/34       Surgical specimen   Direct sequencing   C228T + C250T   NA    NA      5
  Gandolfi et al[@b27-ott-9-6965]    2015   Italy          Retro          Single              121               PTC         NA                 83/38       FFPE                Direct sequencing   C228T + C250T   121   NA      8
  Muzza et al[@b35-ott-9-6965]       2015   Italy          Retro          NA                  182               DTC         NA                 171/69      Surgical specimen   Direct sequencing   C228T + C250T   240   78.9    9
  Qasem et al[@b22-ott-9-6965]       2015   Saudi Arabia   Pro            NA                  265               DTC         34                 201/64      FFPE                Direct sequencing   C228T + C250T   244   6--12   9
  Shi et al[@b36-ott-9-6965]         2015   USA            Retro          Multiple            106               ATC         63.7               65/41       FFPE                Direct sequencing   C228T + C250T   NA    NA      6
  Bullock et al[@b37-ott-9-6965]     2016   Australia      Pro            Single              80                PTC         47.3               66/14       FFPE                Direct sequencing   C228T + C250T   80    106     8
  Myung et al[@b38-ott-9-6965]       2016   Korea          Retro          Single              74                PTC         48                 57/17       FFPE                Direct sequencing   C228T + C250T   74    NA      8
  Bae et al[@b39-ott-9-6965]         2016   Korea          Retro          Single              222               DTC         NA                 173/49      FFPE                Direct sequencing   C228T + C250T   222   NA      5
  Jeon et al[@b40-ott-9-6965]        2016   Korea          Pro            Single              35                PTC         45                 28/7        Surgical specimen   Direct sequencing   C228T           35    66      8
  Jin et al[@b41-ott-9-6965]         2016   China          Retro          Single              653               PTC         46.5               503/150     FFPE                Direct sequencing   C228T + C250T   NA    NA      5
  Sohn et al[@b42-ott-9-6965]        2016   Korea          Retro          Single              19                DTC         59.79              13/6        Surgical specimen   NGS                 C228T + C250T   19    65.95   5

**Abbreviations:** Retro, retrospective; Pro, prospective; TC, all the histological types of thyroid cancer; DTC, differentiated thyroid cancer; FCDTC, follicular-cell-derived thyroid cancer; FTC, follicular thyroid cancer; PTC, papillary thyroid cancer; ATC, anaplastic thyroid cancer; FFPE, formalin-fixed, paraffin-embedded tissues; FNAB, fine-needle aspiration biopsy; CNB, core-needle biopsy; NA, not available; NGS, next-generation sequencing; NOS, Newcastle--Ottawa scale.

###### 

Frequencies of *TERT* promoter mutations in different histological types of thyroid cancer

           C228T   C250T   C228T or C250T                                                                                                                    
  -------- ------- ------- ---------------- ---------------- ------- ------- ----- -------- ---------------- ------- ------- ----- -------- ---------------- -------
  DTC      2,828   258     0.0936           0.0634--0.1238   86.32   2,561   78    0.0284   0.0153--0.0415   75.98   3,587   339   0.1091   0.0819--0.1363   87.55
  PTC      2,443   220     0.0878           0.0586--0.1170   84.98   2,118   63    0.0253   0.0124--0.0382   78.60   3,170   276   0.0941   0.0716--0.1165   79.67
   CPTC    723     77      0.0961           0.0425--0.1497   84.02   340     3     0.0078   0.0075--0.0231   51.35   340     33    0.0342   0.0362--0.1490   70.62
   FVPTC   216     16      0.0636           0.0313--0.0960   23.07   113     2     0.0141   0.0074--0.0357   0       113     10    0.0809   0.0207--0.1824   75.05
   TCPTC   62      17      0.2736           0.1627--0.3845   0       43      1     0.0341   0.0195--0.0876   0       43      13    0.3023   0.1650--0.4396   0
  FTC      160     27      0.1522           0.0973--0.2071   10.09   218     13    0.0393   0.0139--0.0647   13.95   294     53    0.1703   0.1277--0.2128   0
  PDTC     86      27      0.3025           0.2065--0.3984   0       86      12    0.0955   0.0052--0.1857   51.99   131     51    0.3337   0.2068--0.4606   54.37
  ATC      205     80      0.3885           0.3221--0.4549   0       205     9     0.0387   0.0125--0.0649   0       257     103   0.3869   0.2866--0.4872   59.16
  Total    3,654   413     0.1126           0.0820--0.1433   90.65   3,387   109   0.0271   0.0174--0.0368   69.71   4,190   510   0.1428   0.1088--0.1768   92.76

**Abbreviations:** DTC, differentiated thyroid cancer; PTC, papillary thyroid cancer; CPTC, conventional papillary thyroid cancer; FVPTC, follicular-variant papillary thyroid cancer; TCPTC, tall-cell papillary thyroid cancer; FTC, follicular thyroid cancer; PDTC, poorly differentiated thyroid cancer; ATC, anaplastic thyroid cancer; TERT, telomerase reverse transcriptase; CI, confidence interval; *I*^2^, inconsistency index.

###### 

The synergetic effect of *TERT* promoter and *BRAF* mutations in clinicopathological features and adverse outcomes

  Variable                   No of studies   *TERT* + *BRAF* vs *TERT*   *TERT* + *BRAF* vs *BRAF*                                        
  -------------------------- --------------- --------------------------- --------------------------- ------ ------- --------------------- ------
  Age                        5               170                         0.43 (−0.18--1.03)          61.8   1,121   0.77 (0.40--1.15)     70.2
  Gender                     5               170                         3.71 (1.66--8.29)           0      705     2.38 (1.59--3.56)     38.0
  Tumor size                 3               88                          0.80 (0.24--1.35)           0      873     0.69 (−0.26--1.64)    92.6
  Extrathyroidal extension   3               108                         5.85 (2.14--16.01)          16.6   759     5.76 (3.45--9.63)     0
  Vascular invasion          2               73                          0.57 (0.10--3.39)           57.5   223     0.57 (0.097--3.39)    0
  Lymph node metastasis      5               125                         2.08 (0.97--4.49)           0      646     1.58 (1.01--2.47)     0
  Distant metastasis         2               82                          1.47 (0.13--16.82)          73.1   248     13.07 (2.57--66.59)   58.7
  Stage                      5               150                         7.90 (3.22--19.37)          0      1,032   4.22 (2.71--6.58)     25.8
  Recurrence/persistence     3               94                          2.65 (0.41--17.29)          57.1   421     8.50 (4.20--17.19)    4.0
  Mortality                  2               32                          1.38 (0.32--5.98)           0      113     8.14 (2.38--27.89)    29.7

**Abbreviations:** TERT, telomerase reverse transcriptase; OR, odds ratio; CI, confidence interval; *I*^2^, inconsistency index.
